Published in Biol Aujourdhui on July 04, 2012
Pleural effusion in a patient with multiple myeloma. Clin Chem (2012) 2.52
The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res (2004) 1.18
Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev (2004) 1.03
Lumican inhibits angiogenesis by interfering with α2β1 receptor activity and downregulating MMP-14 expression. Thromb Res (2011) 1.03
An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol (2004) 1.00
Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett (2009) 0.98
Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem Biophys Res Commun (2007) 0.98
Lumican inhibits cell migration through α2β1 integrin. Exp Cell Res (2010) 0.96
Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol (2004) 0.96
The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int J Cancer (2010) 0.95
Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors. J Biol Chem (2007) 0.93
Chondroitin sulfate proteoglycans in tumor progression. Adv Pharmacol (2006) 0.92
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res (2004) 0.92
Specific protein-1 is a universal regulator of UDP-glucose dehydrogenase expression: its positive involvement in transforming growth factor-beta signaling and inhibition in hypoxia. J Biol Chem (2003) 0.89
Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLoS One (2012) 0.89
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp Cell Res (2003) 0.89
Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med (2005) 0.88
Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation. Biochim Biophys Acta (2008) 0.87
The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem (2003) 0.87
Lumican affects actin cytoskeletal organization in human melanoma A375 cells. Life Sci (2008) 0.86
Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine. PLoS One (2012) 0.85
Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins. FEBS J (2013) 0.84
The NC1 domain of type XIX collagen inhibits in vivo melanoma growth. Mol Cancer Ther (2007) 0.83
Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin. Chem Biol (2006) 0.81
Influence of aging on glycosaminoglycans and small leucine-rich proteoglycans production by skin fibroblasts. Mol Cell Biochem (2005) 0.80
Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer. Anticancer Res (2007) 0.78
Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. FEBS Lett (2009) 0.78
A crucial role for Lyn in TIMP-1 erythroid cell survival signalling pathway. FEBS Lett (2013) 0.78
Ultraviolet-B irradiation induces epidermal up-regulation of heparanase expression and activity. J Photochem Photobiol B (2011) 0.78
Changes of skin collagen orientation associated with chronological aging as probed by polarized-FTIR micro-imaging. Analyst (2014) 0.78
c-Krox down-regulates the expression of UDP-glucose dehydrogenase in chondrocytes. Biochem Biophys Res Commun (2005) 0.78
Deletion 2q36.2q36.3 with multiple renal cysts and severe mental retardation. Eur J Med Genet (2008) 0.78
The DNA hypomethylating agent, 5-aza-2'-deoxycytidine, enhances tumor cell invasion through a transcription-dependent modulation of MMP-1 expression in human fibrosarcoma cells. Mol Carcinog (2013) 0.77
A new anti-tumor strategy based on in vivo tumstatin overexpression after plasmid electrotransfer in muscle. Biochem Biophys Res Commun (2013) 0.77
The NC1 domain of type XIX collagen inhibits melanoma cell migration. Eur J Dermatol (2010) 0.77
Lumican - derived peptides inhibit melanoma cell growth and migration. PLoS One (2013) 0.77
[Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods]. Ann Biol Clin (Paris) (2013) 0.77
Rapid characterization of glycosaminoglycans using a combined approach by infrared and Raman microspectroscopies. J Pharm Sci (2011) 0.77
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent. Invest New Drugs (2014) 0.77
Investigating the relationship between changes in collagen fiber orientation during skin aging and collagen/water interactions by polarized-FTIR microimaging. Analyst (2015) 0.76
Characterization of glycosaminoglycans by tandem vibrational microspectroscopy and multivariate data analysis. Methods Mol Biol (2012) 0.75
Glycosaminoglycan profiling in different cell types using infrared spectroscopy and imaging. Anal Bioanal Chem (2014) 0.75
Serum folate and vitamin B12: does light really matter? Clin Chem Lab Med (2014) 0.75
[Biological effects of collagen I and IV peptides]. J Soc Biol (2003) 0.75
[Hyperamylasemia after cardiac surgery: which significance?]. Ann Biol Clin (Paris) (2011) 0.75
Interference of M-paraprotein in automated urea assays. Clin Chem Lab Med (2013) 0.75
[Proteolysis directed by the extracellular matrix]. J Soc Biol (2003) 0.75
[Increased plasma C-reactive protein in a pregnant woman with multiple sclerosis: corticotherapy or not ?]. Ann Biol Clin (Paris) (2010) 0.75
[Recommendations for the management of monoclonal gammopathies in biochemistry]. Ann Biol Clin (Paris) (2012) 0.75